ArticleMedicine2026
Bibliometric mapping of the 100 most-cited publications on optic nerve and optic pathway glioma: A cross-sectional bibliometric analysis.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOptic pathway gliomas (OPGs), including optic nerve gliomas, are uncommon tumors of the anterior visual pathway that arise mainly in young children, often with neurofibromatosis type 1 (NF1). The literature is now substantial, but its structure is undescribed. We mapped the most-cited OPG publications to characterize citation patterns, contributors, collaboration, and thematic development.
methodsScopus was searched on April 30, 2025 using a title-abstract-keyword strategy combining 4 OPG-specific phrases, with no year or document-type restriction. Records were ranked by total citations, and the 100 most-cited were retained. Two reviewers screened independently with a 3rd adjudicating; each was then classified by how directly it addressed OPG. Metadata were analyzed in Bibliometrix and VOSviewer. Distributions were assessed with the Shapiro-Wilk test and summarized as medians with interquartile ranges (IQRs); associations used Spearman correlation. Reporting follows the preliminary guideline for reporting bibliometric reviews of the biomedical literature.
resultsThe 100 records, published between 2000 and 2021, were cited 9305 times, with a median of 75 citations per article (IQR 59-108; range 41-289) and a median annual rate of 5.7 (IQR 4.2-7.8). Output peaked in 2010 (n = 9) and again in 2012, 2015, and 2016 (n = 8 each). First authors spanned 17 countries, 53 from the United States. Washington University School of Medicine appeared most often, and David H. Gutmann and Robert A. Avery were the most central authors. Neuro-Oncology (n = 9), Cancer Research (n = 5), and the International Journal of Radiation Oncology Biology Physics (n = 5) led; about four-fifths appeared in 1st-quartile journals. Keyword co-occurrence formed 3 clusters: clinical/chemotherapy, NF1 molecular biology, and imaging/diagnostics. Recent articles were cited faster than older ones (rho = 0.475, publication year vs. annual rate; P < .001). Excluding the 9 peripherally related records left every statistic essentially unchanged (median 76; IQR 59-109).
conclusionAmong the most-cited OPG publications, emphasis has shifted over 2 decades from descriptive clinical series toward NF1 tumor biology, mitogen-activated protein kinase kinase-directed therapy, and quantitative imaging, with output concentrated in a few North American centers. These findings describe how attention has been distributed, not clinical importance or study quality, and are subject to the known limits of citation analysis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.